

# Justification Document for the Selection of a CoRAP Substance

## - UPDATE -

**Substance Name (public name):** sodium 3-nitrobenzene sulphonate

**EC Number:** 204-857-3

**CAS Number:** 127-68-4

**Authority:** Health & Safety Authority, Ireland

**Date:** 22/03/2016

22/03/2022 (1. update)

#### **Cover Note**

This document has been prepared by the evaluating Member State given in the CoRAP update.

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3	Classification  .1.1 Harmonised Classification in Annex VI of the CLP  .1.2 Self classification  .1.3 Proposal for Harmonised Classification in Annex VI of the CLP	<b>5</b> 5 5
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	6
4.1	Tonnage and registration status	6
4.2	Overview of uses	7
	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE RAP SUBSTANCE	E 8
5.1	. Legal basis for the proposal	8
	. Selection criteria met (why the substance qualifies for being in RAP)	8
	. Initial grounds for concern to be clarified under Substance luation	8
	. Preliminary indication of information that may need to be uested to clarify the concern	9
5.5	. Potential follow-up and link to risk management	9


## 1 IDENTITY OF THE SUBSTANCE

## **1.1** Other identifiers of the substance

**Table: Other Substance identifiers** 

EC name (public):	Sodium 3-nitrobenzene sulphonate		
IUPAC name (public):	Sodium 3-nitrobenzene sulfonate		
Index number in Annex VI of the CLP Regulation:	609-048-00-2		
Molecular formula:	C <sub>6</sub> H <sub>5</sub> NO <sub>5</sub> S.Na		
Molecular weight or molecular weight range:	225		
Synonyms:	Benzenesulfonic acid, 3-nitro-, sodium salt		
Type of substance ⊠ Mono-constitue	ent   Multi-constituent   UVCB		

Structural formula:



EC 204-857-3 MSCA - Ireland Page 3 of 9

## **2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION**

## **Table: Completed or ongoing processes**

RMOA	☐ Risk Management Option Analysis (RMOA)			
		□ Compliance check     □		
	Evaluation	☐ Testing proposal		
REACH		☐ CoRAP and Substance Evaluation		
Processes	A the a via a time	☐ Candidate List		
	Authorisation	☐ Annex XIV		
	Restriction	☐ Annex XVII¹		
CLH	⊠ Annex VI (	CLP) (see section 3.1)		
	☐ Plant Protection Products Regulation			
Processes under other	Regulation (EC) No 1107/2009			
EU legislation	☐ Biocidal Product Regulation			
	Regulation (EU) 528/2012 and amendments			
Previous	☐ Dangerous substances Directive 67/548/EEC (NONS)			
legislation	☐ Existing Substances Regulation 793/93/EEC (RAR/RRS)			
(UNEP) Stockholm	☐ Assessment			
convention (POPs Protocol)	☐ In relevant Annex			
Other processes/ EU				
Further details	A compliance check decision was issued in January 2017, which included requests for <i>in vitro</i> gene mutation studies, a sub-chronic toxicity study (90-day), a screening reproductive/developmental toxicity study and a pre-natal developmental toxicity study. The compliance check process was concluded in August 2021.			

 $<sup>^{\</sup>scriptscriptstyle 1}$  Please specify the relevant entry.

## 3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

#### 3.1 Classification

#### 3.1.1 Harmonised Classification in Annex VI of the CLP

**Table: Harmonised classification** 

Index No	International Chemical Identification	EC No	CAS No	Classification		Spec. Conc. Limits,	Notes
				Hazard Class and Category Code(s)	Hazard statement code(s)	M- factors	
609-048- 00-2	sodium 3- nitrobenzenesul phonate	204- 857-3	127-68- 4	Skin Sens. 1 Eye Irrit. 2	H317 H319		

#### 3.1.2 Self classification

- In the registration:
  - Skin sensitisation 1; H317: May cause an allergic skin reaction
  - Eye irritation 2; H319: Causes serious eye irritation
- The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:
  - A number of notifications have concluded the substance is "not classified"

## 3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

None.

## 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES<sup>2</sup>

## 4.1 Tonnage and registration status

**Table: Tonnage and registration status** 

From ECHA dissemination site *					
□ Full registration(s) (Art. 10)		☐ Intermediate registration(s) (Art. 17 and/or 18)			
Tonnage band (as per dissemina	ation s	ite)			
□ 1 - 10 tpa		0 – 100 tpa	□ 100 – 1000 tpa		
⊠ 1000 - 10,000 tpa	□ 10,000 - 100,000 tpa		□ 100,000 - 1,000,000 tpa		
□ 1,000,000 - 10,000,000 tpa	☐ 10,000,000 - 100,000,000 tpa		□ > 100,000,000 tpa		
□ <1>+ tpa	☐ Confidential				
One joint submission with eight active registrants					

https://echa.europa.eu/documents/10162/22308542/manual\_dissemination\_en.pdf/7e0b8 7c2-2681-4380-8389-cd655569d9f0

EC 204-857-3 MSCA - Ireland Page 6 of 9

<sup>\*</sup>the total tonnage band has been calculated by excluding the intermediate uses, for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11):

<sup>&</sup>lt;sup>2</sup> Accessed October 2021

## **4.2 Overview of uses**

Table: Uses

#### Part 1:

	$\boxtimes$	$\boxtimes$	$\boxtimes$		⊠ Article	☐ Closed
Manufacture	Formulation	Industrial	Professional	Consumer	service life	system
		use	use	use		

#### Part 2:

ait 2.	
	Use(s)
Uses as intermediate	-
Formulation	Formulation of the substance
Uses at industrial sites	Intermediate; electroplating agent; catalyst; metal surface treatment; textile coating
Uses by professional workers	Textiles
<b>Consumer Uses</b>	-
Article service life	Textiles, machinery, mechanical appliances, electrical/electronic articles; electrical batteries and accumulators; metal articles

### 5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP **SUBSTANCE**

5.1. Le	5.1. Legal basis for the proposal						
⊠ Article	44(2)						
☐ Article	45(5)						
5.2. S	election criteria met	(why the substance qualifies	s for being in CoRAP)				
	criteria as CMR/ Suspect	ed CMR					
☐ Fulfils	criteria as Sensitiser/ Su	spected sensitiser					
☐ Fulfils	criteria as potential endo	crine disrupter					
☐ Fulfils	criteria as PBT/vPvB / Su	spected PBT/vPvB					
□ Fulfils	criteria high (aggregated	) tonnage ( <i>tpa</i> > 1000)					
☐ Fulfils	exposure criteria						
☐ Fulfils	MS's (national) priorities						
5.3. Ir	nitial grounds for con	cern to be clarified unde	r Substance Evaluatior				
Hazaı	rd based concerns						
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$							
☐ Sensitiser ☐ Suspected Sensitiser³							
□ PB <sup>-</sup>	$\square$ PBT/vPvB $\square$ Suspected PBT/vPvB <sup>1</sup> $\square$ Other (please specify below)						
Expos	sure/risk based concer	ns					
	□ Wide dispersive use □ Consumer use □ Exposure of sensitive						

In the 90-day oral repeated dose toxicity study with sodium 3-nitrobenzene sulphonate, an increase in absolute testes weight was observed in the mid and high dose groups. The registration dossier includes a valid data waiver for the screening

tonnage

☐ Consumer use

populations

below)

☐ Cumulative exposure

☐ Other (please specify

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

☐ Wide dispersive use

☐ High RCR

☐ Exposure of environment

<sup>&</sup>lt;sup>3</sup> <u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant selfclassification)

#### JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE

reproductive/developmental toxicity study (Annex VIII, section 8.7.1) and therefore no data addressing effects on fertility is available. No concern for developmental toxicity was identified from the pre-natal developmental toxicity study in rats with sodium 3-

nitrobenzene sulphonate.

Sodium 3-nitrobenzene sulphonate is structurally similar to nitrobenzene (EC 202-716-0), which has a harmonized classification as Repr. 1B H360F due to effects on male fertility. No concern for developmental toxicity has been identified for nitrobenzene. In a previous version of the registration dossier, the registrants of sodium 3-nitrobenzene sulphonate applied a "negative" read-across from nitrobenzene to address effects on development. However, no "positive" read-across from nitrobenzene to address effects on fertility was applied.

The registration data reports industrial and professional uses of sodium 3-nitrobenzene sulphonate. In addition, use in a number of article types is reported.

A further review of the available data is required in order to determine whether further data is needed to clarify the concern for reproductive toxicity (effects on fertility) for sodium 3-nitrobenzene sulphonate.

## **5.4.** Preliminary indication of information that may need to be requested to clarify the concern

$oxed{\boxtimes}$ Information on toxicological properties	☐ Information on physico-chemical properties			
$\square$ Information on fate and behaviour	$\square$ Information on exposure			
$\hfill\Box$ Information on ecotoxicological properties	$\square$ Information on uses			
☐ Information ED potential	☐ Other (provide further details below)			
Following the evaluation of the existing data, further information may be requested to address reproductive toxicity (effects on fertility).				

#### 5.5. Potential follow-up and link to risk management

□ Harmonised C&L	☐ Restriction	☐ Authorisation	☐ Other (provide further details)				
Where the concern for reproductive toxicity (effects on fertility) is verified, the need for harmonized classification and labelling will be assessed.							

EC 204-857-3 MSCA - Ireland Page 9 of 9